{"id":"lincomycin","rwe":[],"_fda":{"id":"e2cf9f04-64e0-4a9c-e053-2a95a90a25ba","set_id":"20c0e8af-a78f-47f8-ace4-06b80def7003","openfda":{"unii":["M6T05Z2B68"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["239212"],"spl_id":["e2cf9f04-64e0-4a9c-e053-2a95a90a25ba"],"brand_name":["Lincomycin"],"spl_set_id":["20c0e8af-a78f-47f8-ace4-06b80def7003"],"package_ndc":["42571-374-75","42571-374-88"],"product_ndc":["42571-374"],"generic_name":["LINCOMYCIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["LINCOMYCIN HYDROCHLORIDE"],"manufacturer_name":["Micro Labs Limited"],"application_number":["ANDA215082"],"is_original_packager":[true]},"version":"13","warnings":["WARNINGS See BOXED WARNING . Clostridioides difficile associated diarrhea Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Lincomycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Hypersensitivity Severe hypersensitivity reactions, including anaphylactic reactions and severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and erythema multiforme (EM) have been reported in patients receiving lincomycin therapy. If an anaphylactic reaction or severe skin reaction occurs, lincomycin should be discontinued and appropriate therapy should be initiated. (see ADVERSE REACTIONS ) Benzyl Alcohol Toxicity in Pediatric Patients (Gasping Syndrome) Lincomycin injection contains benzyl alcohol as a preservative. The preservative benzyl alcohol has been associated with serious adverse events, including the “gasping syndrome”, and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the “gasping syndrome”, the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys’ capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity. Inadequate for Use in Meningitis Although lincomycin appears to diffuse into cerebrospinal fluid, concentrations of lincomycin in the CSF may be inadequate for the treatment of meningitis."],"pregnancy":["Pregnancy There are no adequate and well-controlled studies in pregnant women. Lincomycin Sterile Solution contains benzyl alcohol as a preservative. Benzyl alcohol can cross the placenta. See WARNINGS . Lincomycin should be used during pregnancy only if clearly needed. Teratogenic Effects: In a study with 60 pregnant women, cord serum concentrations were approximately 25% of the maternal serum concentrations, indicating that lincomycin crosses the placenta, and no substantial accumulation occurred in the amniotic fluid. Experience with 345 obstetrical patients receiving lincomycin revealed no ill effects related to pregnancy. There was no evidence of teratogenicity when lincomycin was administered in diet to pregnant Sprague Dawley rats during the period of major organogenesis at doses up to 5000 mg/kg (approximately 6 times the maximum recommended human dose [MRHD], respectively, based on body surface area comparison). Nonteratogenic Effects: Reproduction studies performed in rats administered oral lincomycin in diet for 2 weeks prior to mating, throughout pregnancy and lactation, revealed no adverse effects on survival of offspring from birth to weaning at doses up to 1000 mg/kg (1.2 times the MRHD based on body surface area comparison) up to 2 generations."],"overdosage":["OVERDOSAGE Serum concentrations of lincomycin are not appreciably affected by hemodialysis and peritoneal dialysis."],"description":["DESCRIPTION Lincomycin injection, USP is a sterile solution containing lincomycin hydrochloride which is the monohydrated salt of lincomycin, a lincosamide antibacterial produced by the growth of a member of the lincolnensis group of Streptomyces lincolnensis (Fam. Streptomycetaceae ). The chemical name for lincomycin hydrochloride is Methyl 6,8-dideoxy-6-(1-methyl-trans-4-propyl-L­2-pyrolidinecarboxamido)-1-thio-D-erythro-α-D-galacto-octopyranoside monohydrochloride monohydrate. The molecular formula of lincomycin hydrochloride is C 18 H 34 N 2 O 6 S.HCl.H 2 O and the molecular weight is 461.01. The structural formula is represented below: Lincomycin hydrochloride is a white or practically white, crystalline powder. Its solutions are acid and are dextrorotatory. Lincomycin hydrochloride is freely soluble in water; soluble in dimethylformamide and insoluble in acetone. Lincomycin Injection, USP contains lincomycin hydrochloride in a sterile, clear, colorless to slightly yellow solution with benzyl alcohol used as a preservative 9.45 mg/mL, and water for injection. Lincomycin injection, USP is a sterile solution for intramuscular and intravenous use. Lincomycin injection, USP is supplied in 2 mL and 10 mL multiple-dose vials containing 300 mg/mL of lincomycin (equivalent to 340 mg/mL of lincomycin hydrochloride, USP). strc"],"precautions":["PRECAUTIONS General Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When lincomycin is indicated in these patients, they should be carefully monitored for change in bowel frequency. Lincomycin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Lincomycin should be used with caution in patients with a history of asthma or significant allergies. Certain infections may require incision and drainage or other indicated surgical procedures in addition to antibacterial therapy. The use of lincomycin may result in overgrowth of nonsusceptible organisms, particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation. When patients with pre-existing Candida infections require therapy with lincomycin, concomitant antifungal treatment should be given. The serum half-life of lincomycin may be prolonged in patients with severe renal impairment compared to patients with normal renal function. In patients with hepatic impairment, serum half-life may be twofold longer than in patients with normal hepatic function. Patients with severe renal impairment and/or hepatic impairment should be dosed with caution and serum lincomycin concentrations monitored during high-dose therapy. (see DOSAGE AND ADMINISTRATION ) Lincomycin MUST be diluted prior to intravenous infusion. For intravenous infusion, infuse over at least 60 minutes as directed in the DOSAGE AND ADMINISTRATION Section. Do NOT administer as an intravenous bolus. Severe cardiopulmonary reactions have occurred at greater than the recommended concentration and rate. Prescribing lincomycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Information for Patients Patients should be counseled that antibacterial drugs including lincomycin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When lincomycin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by lincomycin or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibacterial which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with an antibacterial, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after taking the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible. Laboratory Tests During prolonged therapy with lincomycin, periodic liver and kidney function tests and blood counts should be performed. Drug Interactions Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; therefore, it should be used with caution in patients receiving such agents. Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of lincomycin has not been evaluated. Lincomycin was not found to be mutagenic in the Ames Salmonella reversion assay or the V79 Chinese hamster lung cells at the HGPRT locus. It did not induce DNA strand breaks in V79 Chinese hamster lung cells as measured by alkaline elution or chromosomal abnormalities in cultured human lymphocytes. In vivo , lincomycin was negative in both the rat and mouse micronucleus assays and it did not induce sex-linked recessive lethal mutations in the offspring of male Drosophila. However, lincomycin did cause unscheduled DNA syntheses in freshly isolated rat hepatocytes. Impairment of fertility was not observed in male or female rats given oral 300 mg/kg doses of lincomycin (0.36 times the highest recommended human dose based on mg/m 2 ). Pregnancy There are no adequate and well-controlled studies in pregnant women. Lincomycin Sterile Solution contains benzyl alcohol as a preservative. Benzyl alcohol can cross the placenta. See WARNINGS . Lincomycin should be used during pregnancy only if clearly needed. Teratogenic Effects: In a study with 60 pregnant women, cord serum concentrations were approximately 25% of the maternal serum concentrations, indicating that lincomycin crosses the placenta, and no substantial accumulation occurred in the amniotic fluid. Experience with 345 obstetrical patients receiving lincomycin revealed no ill effects related to pregnancy. There was no evidence of teratogenicity when lincomycin was administered in diet to pregnant Sprague Dawley rats during the period of major organogenesis at doses up to 5000 mg/kg (approximately 6 times the maximum recommended human dose [MRHD], respectively, based on body surface area comparison). Nonteratogenic Effects: Reproduction studies performed in rats administered oral lincomycin in diet for 2 weeks prior to mating, throughout pregnancy and lactation, revealed no adverse effects on survival of offspring from birth to weaning at doses up to 1000 mg/kg (1.2 times the MRHD based on body surface area comparison) up to 2 generations. Nursing Mothers Lincomycin has been reported to appear in human milk in concentrations of 0.5 to 2.4 mcg/mL. Because of the potential for serious adverse reactions in nursing infants from lincomycin, a decision should be made whether to discontinue nursing, or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Lincomycin injection contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal “Gasping Syndrome” in premature infants. See WARNINGS . Safety and effectiveness in pediatric patients below the age of one month have not been established. (see DOSAGE AND ADMINISTRATION )"],"how_supplied":["HOW SUPPLIED Lincomycin Injection, USP is a sterile, clear, colorless to slightly yellow solution, having a slight odor. Free from any visible particles available in the following strength and package sizes: Unit of Sale Concentration NDC 42571-374-75 2 mL multiple-dose vial 600 mg/2 mL (300 mg/mL) NDC 42571-374-88 10 mL multiple-dose vial 3,000 mg/10 mL (300 mg/mL) Each mL of Lincomycin Injection, USP contains 300 mg lincomycin (equivalent to 340 mg lincomycin hydrochloride, USP); also benzyl alcohol, 9.45 mg added as preservative. Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]."],"boxed_warning":["WARNING Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. diffficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated."],"pediatric_use":["Pediatric Use Lincomycin injection contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal “Gasping Syndrome” in premature infants. See WARNINGS . Safety and effectiveness in pediatric patients below the age of one month have not been established. (see DOSAGE AND ADMINISTRATION )"],"effective_time":"20220702","nursing_mothers":["Nursing Mothers Lincomycin has been reported to appear in human milk in concentrations of 0.5 to 2.4 mcg/mL. Because of the potential for serious adverse reactions in nursing infants from lincomycin, a decision should be made whether to discontinue nursing, or to discontinue the drug, taking into account the importance of the drug to the mother."],"laboratory_tests":["Laboratory Tests During prolonged therapy with lincomycin, periodic liver and kidney function tests and blood counts should be performed."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions have been reported with the use of lincomycin. Gastrointestinal disorders Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort†, anal pruritus Skin and subcutaneous tissue disorders Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, dermatitis bullous, dermatitis exfoliative, erythema multiforme (see WARNINGS ), rash, urticaria, pruritus Infections and infestations Vaginal infection, pseudomembranous colitis, Clostridioides difficile colitis (see WARNINGS ) Blood and lymphatic system disorders Pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpura Immune system disorders Anaphylactic reaction (see WARNINGS ), angioedema, serum sickness Hepatobiliary disorders Jaundice, liver function test abnormal, transaminases increased Renal and urinary disorders Renal impairment, oliguria, proteinuria, azotemia Cardiac disorders Cardio-respiratory arrest (see DOSAGE AND ADMINISTRATION ) Vascular disorders Hypotension (see DOSAGE AND ADMINISTRATION ), thrombophlebitis† Ear and labyrinth disorders Vertigo, tinnitus Neurologic disorders Headache, dizziness, somnolence General disorders and administration site conditions Injection site abscess sterile‡, injection site induration‡, injection site pain‡, injection site irritation‡ †Event has been reported with intravenous injection. ‡Reported with intramuscular injection. To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA, Inc. at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Lincomycin injection is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin."],"drug_interactions":["Drug Interactions Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; therefore, it should be used with caution in patients receiving such agents."],"how_supplied_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">Unit of Sale</content> </td><td styleCode=\"Rrule\" valign=\"middle\"><content styleCode=\"bold\">Concentration </content> </td></tr><tr styleCode=\"Botrule\"><td align=\"justify\" styleCode=\"Lrule Rrule\" valign=\"middle\"> <content styleCode=\"bold\">NDC 42571-374-75</content>  2 mL multiple-dose vial </td><td align=\"justify\" styleCode=\"Rrule\" valign=\"middle\"> 600 mg/2 mL   (300 mg/mL) </td></tr><tr><td align=\"justify\" styleCode=\"Lrule Rrule\" valign=\"middle\"> <content styleCode=\"bold\">NDC 42571-374-88</content>  10 mL multiple-dose vial </td><td align=\"justify\" styleCode=\"Rrule\" valign=\"middle\"> 3,000 mg/10 mL   (300 mg/mL) </td></tr></tbody></table>"],"general_precautions":["General Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When lincomycin is indicated in these patients, they should be carefully monitored for change in bowel frequency. Lincomycin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Lincomycin should be used with caution in patients with a history of asthma or significant allergies. Certain infections may require incision and drainage or other indicated surgical procedures in addition to antibacterial therapy. The use of lincomycin may result in overgrowth of nonsusceptible organisms, particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation. When patients with pre-existing Candida infections require therapy with lincomycin, concomitant antifungal treatment should be given. The serum half-life of lincomycin may be prolonged in patients with severe renal impairment compared to patients with normal renal function. In patients with hepatic impairment, serum half-life may be twofold longer than in patients with normal hepatic function. Patients with severe renal impairment and/or hepatic impairment should be dosed with caution and serum lincomycin concentrations monitored during high-dose therapy. (see DOSAGE AND ADMINISTRATION ) Lincomycin MUST be diluted prior to intravenous infusion. For intravenous infusion, infuse over at least 60 minutes as directed in the DOSAGE AND ADMINISTRATION Section. Do NOT administer as an intravenous bolus. Severe cardiopulmonary reactions have occurred at greater than the recommended concentration and rate. Prescribing lincomycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Intramuscular administration of a single dose of 600 mg of lincomycin produces average peak serum concentrations of 11.6 mcg/mL at 60 minutes and maintains therapeutic concentrations for 17 to 20 hours for most susceptible gram-positive organisms. Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 17.3 percent). A two hour intravenous infusion of 600 mg of lincomycin achieves average peak serum concentrations of 15.9 mcg/mL and maintains therapeutic concentrations for 14 hours for most susceptible gram-positive organisms. Urinary excretion ranges from 4.9 to 30.3 percent (mean: 13.8 percent). The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe renal impairment compared to patients with normal renal function. In patients with hepatic impairment, serum half-life may be twofold longer than in patients with normal hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing lincomycin from the serum. Tissue distribution studies indicate that bile is an important route of excretion. Significant concentrations have been demonstrated in most body tissues. Although lincomycin appears to diffuse into cerebrospinal fluid (CSF), concentrations of lincomycin in the CSF appear inadequate for the treatment of meningitis. Microbiology: Mechanism of Action Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro . Resistance Cross resistance has been demonstrated between clindamycin and lincomycin. Resistance is most often due to methylation of specific nucleotides in the 23S RNA of the 50S ribosomal subunit, which can determine cross resistance to macrolides and streptogramins B (MLSB phenotype). Macrolide-resistant isolates of these organisms should be tested for inducible resistance to lincomycin/clindamycin using the D-zone test or other appropriate method. Antimicrobial Activity Lincomycin has been shown to be active against most strains of the following bacteria both in vitro and in clinical infections: (see INDICATIONS AND USAGE ). Staphylococcus aureus Streptococcus pneumoniae The following in vitro data are available, but their clinical significance is unknown. Lincomycin has been shown to be active in vitro against the following microorganisms; however, the safety and efficacy of lincomycin in treating clinical infections due to these organisms have not been established in adequate and well controlled trials. Gram-positive bacteria: Corynebacterium diphtheriae Streptococcus pyogenes Viridans group streptococci Anaerobic bacteria: Clostridium tetani Clostridium perfringens Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["INDICATIONS AND USAGE Lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"information_for_patients":["Information for Patients Patients should be counseled that antibacterial drugs including lincomycin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When lincomycin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by lincomycin or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibacterial which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with an antibacterial, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after taking the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible."],"spl_unclassified_section":["To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.","PHYSICAL COMPATIBILITIES Physically compatible for 24 hours at room temperature unless otherwise indicated. Infusion Solutions 5% Dextrose Injection 10% Dextrose Injection 5% Dextrose and 0.9% Sodium Chloride Injection 10% Dextrose and 0.9% Sodium Chloride Injection Ringer’s Injection 1/6 M Sodium Lactate Injection Travert 10%-Electrolyte No. 1 Dextran in Saline 6% w/v Vitamins in Infusion Solutions B-Complex B-Complex with Ascorbic Acid Antibacterial in Infusion Solutions Penicillin G Sodium (Satisfactory for 4 hours) Cephalothin Tetracycline HCl Cephaloridine Colistimethate (Satisfactory for 4 hours) Ampicillin Methicillin Chloramphenicol Polymyxin B Sulfate Physically Incompatible with: Novobiocin Kanamycin IT SHOULD BE EMPHASIZED THAT THE COMPATIBLE AND INCOMPATIBLE DETERMINATIONS ARE PHYSICAL OBSERVATIONS ONLY, NOT CHEMICAL DETERMINATIONS. ADEQUATE CLINICAL EVALUATION OF THE SAFETY AND EFFICACY OF THESE COMBINATIONS HAS NOT BEEN PERFORMED. Rx only Manufactured by: Micro Labs Limited Bangalore-560099, INDIA. Manufactured for: Micro Labs USA, Inc. Somerset, NJ 08873 Rev.07/2022"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION If significant diarrhea occurs during therapy, lincomycin should be discontinued. (see BOXED WARNING ) INTRAMUSCULAR - Adults: Serious infections —600 mg (2 mL) intramuscularly every 24 hours. More severe infections —600 mg (2 mL) intramuscularly every 12 hours or more often. Pediatric patients over 1 month of age: Serious infections —one intramuscular injection of 10 mg/kg (5 mg/lb) every 24 hours. More severe infections — one intramuscular injection of 10 mg/kg (5 mg/lb) every 12 hours or more often. INTRAVENOUS - Adults: The intravenous dose will be determined by the severity of the infection. For serious infections doses of 600 mg of lincomycin (2 mL of lincomycin) to 1 gram are given every 8 to 12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given. Intravenous doses are given on the basis of 1 gram of lincomycin diluted in not less than 100 mL of appropriate solution (see PHYSICAL COMPATIBILITIES) and infused over a period of not less than one hour. Dose Vol. Diluent Time 600 mg 100 mL 1 hr 1 gram 100 mL 1 hr 2 grams 200 mL 2 hr 3 grams 300 mL 3 hr 4 grams 400 mL 4 hr These doses may be repeated as often as required to the limit of the maximum recommended daily dose of 8 grams of lincomycin. Pediatric patients over 1 month of age: 10 to 20 mg/kg/day (5 to 10 mg/lb/day) depending on the severity of the infection may be infused in divided doses as described above for adults. NOTE: Severe cardiopulmonary reactions have occurred when lincomycin has been given at greater than the recommended concentration and rate (see PRECAUTIONS ). SUBCONJUNCTIVAL INJECTION - 0.25 mL (75 mg) injected subconjunctivally will result in ocular fluid concentrations of antibacterial (lasting for at least 5 hours) sufficient for most susceptible pathogens. Patients with Renal Impairment When therapy with lincomycin is required in individuals with severe renal impairment, an appropriate dose is 25 to 30% of that recommended for patients with normally functioning kidneys (see PRECAUTIONS ). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."],"spl_product_data_elements":["Lincomycin Lincomycin BENZYL ALCOHOL LINCOMYCIN HYDROCHLORIDE LINCOMYCIN"],"dosage_and_administration_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><col width=\"33.34%\"/><col width=\"33.34%\"/><col width=\"33.32%\"/><tbody><tr styleCode=\"Botrule\"><td align=\"left\" styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\"> Dose</content> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"> <content styleCode=\"bold\">Vol.</content><content styleCode=\"bold\"> Diluent</content> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"> <content styleCode=\"bold\">Time</content></td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"> 600 mg </td><td align=\"left\" styleCode=\"Rrule\" valign=\"top\">100 mL  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"> 1 hr </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\">1 gram  </td><td align=\"left\" styleCode=\"Rrule\" valign=\"top\">100 mL  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"> 1 hr </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"> 2 grams </td><td align=\"left\" styleCode=\"Rrule\" valign=\"top\">200 mL  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"> 2 hr </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"> 3 grams </td><td align=\"left\" styleCode=\"Rrule\" valign=\"top\">300 mL  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"> 3 hr </td></tr><tr><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"> 4 grams </td><td align=\"left\" styleCode=\"Rrule\" valign=\"top\">400 mL  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"> 4 hr </td></tr></tbody></table>"],"animal_pharmacology_and_or_toxicology":["ANIMAL PHARMACOLOGY In vivo experimental animal studies demonstrated the effectiveness of lincomycin preparations (lincomycin) in protecting animals infected with Streptococcus viridans, β- hemolytic Streptococcus, Staphylococcus aureus, Streptococcus pneumoniae and Leptospira pomona. It was ineffective in Klebsiella, Pasteurella, Pseudomonas, Salmonella and Shigella infections ."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC-42571-374-75 Lincomycin Injection, USP 600 mg/ 2 mL* (300 mg/mL) For Intramuscular Use or Intravenous Use Rx only 2 mL Multiple-dose Vial Micro Labs Limited NDC-42571-374-88 Lincomycin Injection, USP 3,000 mg/ 10 mL* (300 mg/mL) For Intramuscular Use or Intravenous Use Rx only 10 mL Multiple-dose Vial Micro Labs Limited lincomycin-2ml.jpg lincomycin-10ml.jpg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of lincomycin has not been evaluated. Lincomycin was not found to be mutagenic in the Ames Salmonella reversion assay or the V79 Chinese hamster lung cells at the HGPRT locus. It did not induce DNA strand breaks in V79 Chinese hamster lung cells as measured by alkaline elution or chromosomal abnormalities in cultured human lymphocytes. In vivo , lincomycin was negative in both the rat and mouse micronucleus assays and it did not induce sex-linked recessive lethal mutations in the offspring of male Drosophila. However, lincomycin did cause unscheduled DNA syntheses in freshly isolated rat hepatocytes. Impairment of fertility was not observed in male or female rats given oral 300 mg/kg doses of lincomycin (0.36 times the highest recommended human dose based on mg/m 2 )."]},"tags":[{"label":"lincomycin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01FF02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Pneumococcal infectious disease","category":"indication"},{"label":"Staphylococcal infectious disease","category":"indication"},{"label":"Streptococcal infectious disease","category":"indication"},{"label":"Pfizer","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. diffficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated."],"safetySignals":[{"llr":282.7,"date":"","count":86,"signal":"Drug hypersensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=283)"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Glossitis","drugRate":"reported","severity":"unknown"},{"effect":"Stomatitis","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal discomfort","drugRate":"reported","severity":"unknown"},{"effect":"Anal pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Toxic epidermal necrolysis","drugRate":"reported","severity":"unknown"},{"effect":"Stevens-Johnson syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Acute generalized exanthematous pustulosis","drugRate":"reported","severity":"unknown"},{"effect":"Dermatitis bullous","drugRate":"reported","severity":"unknown"},{"effect":"Dermatitis exfoliative","drugRate":"reported","severity":"unknown"},{"effect":"Erythema multiforme","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Vaginal infection","drugRate":"reported","severity":"unknown"},{"effect":"Pseudomembranous colitis","drugRate":"reported","severity":"unknown"},{"effect":"Clostridium difficile colitis","drugRate":"reported","severity":"unknown"},{"effect":"Pancytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Leukopenia","drugRate":"reported","severity":"unknown"},{"effect":"Neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenic purpura","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylactic reaction","drugRate":"reported","severity":"unknown"},{"effect":"Angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Serum sickness","drugRate":"reported","severity":"unknown"},{"effect":"Jaundice","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Colitis","Disorder of digestive system","Hepatic failure","Pseudomembranous enterocolitis"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. Lincomycin injection sterile solution contains benzyl alcohol as preservative. Benzyl alcohol can cross the placenta. See WARNINGS. Lincomycin injection should be used during pregnancy only if clearly needed.. Teratogenic Effects In study with 60 pregnant women, cord serum concentrations were approximately 25% of the maternal serum concentrations, indicating that lincomycin crosses the placenta, and no substantial ac","Paediatric use":"Lincomycin injection sterile solution contains benzyl alcohol as preservative. Benzyl alcohol has been associated with fatal Gasping Syndrome in premature infants (see WARNINGS). Safety and effectiveness in pediatric patients below the age of one month have not been established (see DOSAGE AND ADMINISTRATION)."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LINCOMYCIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:13:42.432822+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Lincomycin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:13:49.768258+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:13:48.343614+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LINCOMYCIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:13:48.616927+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:41.322641+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inap","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:41.322663+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: 70S ribosome inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:13:49.768201+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989551/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:13:49.423343+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA215082","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:41.322666+00:00"}},"allNames":"lincocin","offLabel":[],"synonyms":["lincomycin","cillimycin","jiemycin","Lincomycin A","medoglycine","lincomycin hydrochloride","lincomycin HCl","lincomycin hydrochloride monohydrate"],"timeline":[{"date":"1964-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PHARMACIA AND UPJOHN to Pfizer"},{"date":"1964-12-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pharmacia And Upjohn)"},{"date":"1991-04-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Lincocin (Lincomycin) is a small molecule antibiotic in the lincomycin class, originally developed by Pharmacia and Upjohn and currently owned by Pfizer. It was FDA-approved in 1964 for the treatment of pneumococcal, staphylococcal, and streptococcal infectious diseases. Lincocin is off-patent and has multiple generic manufacturers. The drug has a half-life of 5.6 hours and bioavailability of 25%. It is used to treat bacterial infections caused by susceptible organisms.","approvals":[{"date":"1964-12-29","orphan":false,"company":"PHARMACIA AND UPJOHN","regulator":"FDA"}],"brandName":"Lincocin","ecosystem":[{"indication":"Pneumococcal infectious disease","otherDrugs":[],"globalPrevalence":null},{"indication":"Staphylococcal infectious disease","otherDrugs":[{"name":"nafcillin","slug":"nafcillin","company":"Wyeth Ayerst"},{"name":"oxacillin","slug":"oxacillin","company":"Sandoz"},{"name":"vancomycin","slug":"vancomycin","company":""}],"globalPrevalence":null},{"indication":"Streptococcal infectious disease","otherDrugs":[{"name":"benzathine benzylpenicillin","slug":"benzathine-benzylpenicillin","company":"King Pharms"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"},{"name":"procaine benzylpenicillin","slug":"procaine-benzylpenicillin","company":"King Pharms"}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"lincomycin","explanation":"","oneSentence":"","technicalDetail":"Lincocin exerts its antibacterial effects by binding to the 50S subunit of the bacterial ribosome, inhibiting peptide bond formation and thus preventing protein synthesis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lincomycin","title":"Lincomycin","extract":"Lincomycin is a lincosamide antibiotic that comes from the actinomycete Streptomyces lincolnensis. A related compound, clindamycin, is derived from lincomycin by using thionyl chloride to replace the 7-hydroxy group with a chlorine atom with inversion of chirality. It was released for medical use in September 1964."},"commercial":{"launchDate":"1964","_launchSource":"DrugCentral (FDA 1964-12-29, PHARMACIA AND UPJOHN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1582","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LINCOMYCIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LINCOMYCIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Lincomycin","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:21:54.551577","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:13:53.029244+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"clindamycin","drugSlug":"clindamycin","fdaApproval":"1970-02-22","patentExpiry":"Sep 22, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"lincomycin","indications":{"approved":[{"name":"Pneumococcal infectious disease","source":"DrugCentral","snomedId":16814004,"regulator":"FDA","eligibility":"Penicillin-allergic patients or other patients for whom, in the judgment of the physician, penicillin is inappropriate"},{"name":"Staphylococcal infectious disease","source":"DrugCentral","snomedId":56038003,"regulator":"FDA","eligibility":"Penicillin-allergic patients or other patients for whom, in the judgment of the physician, penicillin is inappropriate"},{"name":"Streptococcal infectious disease","source":"DrugCentral","snomedId":85769006,"regulator":"FDA","eligibility":"Penicillin-allergic patients or other patients for whom, in the judgment of the physician, penicillin is inappropriate"}],"offLabel":[],"pipeline":[]},"currentOwner":"Pfizer","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"clindamycin","brandName":"clindamycin","genericName":"clindamycin","approvalYear":"1970","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04580472","phase":"PHASE4","title":"Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carilion Clinic","startDate":"2020-10-01","conditions":["Surgical Site Infection"],"enrollment":574,"completionDate":"2026-09"},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":300,"completionDate":"2032-01-31"},{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":["Community Acquired Pneumonia in Children"],"enrollment":236,"completionDate":"2028-05"},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":["Endocarditis Infective"],"enrollment":360,"completionDate":"2027-12-30"},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":["Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI"],"enrollment":1600,"completionDate":"2027-07-31"},{"nctId":"NCT04039750","phase":"PHASE2","title":"Use of Antibiotic Irrigation to Decrease Wound Infections in Pediatric Perforated Appendicitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prisma Health-Upstate","startDate":"2019-07-25","conditions":["Perforated Appendicitis"],"enrollment":200,"completionDate":"2026-12"},{"nctId":"NCT07267013","phase":"PHASE2","title":"Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC)","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-30","conditions":["Aortic Surgery","Extracorporeal Circulation"],"enrollment":25,"completionDate":"2026-10-30"},{"nctId":"NCT07357103","phase":"PHASE4","title":"Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-03","conditions":["Pneumocystis","Pneumocystis Infection","Pneumocystis Carinii Infection","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystis Jirovecii Pneumonia","Pneumocystis Jirovecii Infection","Pneumocystosis Associated With AIDS","Pneumocystosis; Pneumonia (Etiology)"],"enrollment":416,"completionDate":"2029-09"},{"nctId":"NCT01722708","phase":"NA","title":"Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-11-01","conditions":["Abnormal Vaginal Flora","Clindamycin Vs Metronidazole","High Risk Pregnancies for Preterm Labor"],"enrollment":166,"completionDate":"2025-12-30"},{"nctId":"NCT05582434","phase":"EARLY_PHASE1","title":"Experience With Topical Acne Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-15","conditions":["Acne"],"enrollment":72,"completionDate":"2026-11"},{"nctId":"NCT05206500","phase":"PHASE4","title":"NextGen - Clinical Implication of Next Generation Sequencing","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-05-17","conditions":["Urinary Tract Infections"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT02309346","phase":"PHASE4","title":"Clindamycin Once a Day in Septic Abortion","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12-17","conditions":["Septic Abortion"],"enrollment":202,"completionDate":"2023-12-31"},{"nctId":"NCT05137119","phase":"PHASE4","title":"Staphylococcus Aureus Network Adaptive Platform Trial","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-16","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":8000,"completionDate":"2028-12-01"},{"nctId":"NCT05846399","phase":"PHASE4","title":"CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2023-09-07","conditions":["Cat Bite","Hand Injuries","Arm Injury","Infection, Bacterial","Anti-bacterial Agents"],"enrollment":72,"completionDate":"2027-08-01"},{"nctId":"NCT00642980","phase":"PHASE4","title":"Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2006-04","conditions":["Pregnancy"],"enrollment":3105,"completionDate":"2011-06"},{"nctId":"NCT04104178","phase":"PHASE3","title":"Optimal Treatment of MRSA Throat Carriers","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2020-05-20","conditions":["MRSA","MRSA Colonization"],"enrollment":53,"completionDate":"2025-09-18"},{"nctId":"NCT04502095","phase":"PHASE4","title":"Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-09-02","conditions":["Bladder Carcinoma","Refractory Bladder Carcinoma","Urinary Tract Infection"],"enrollment":89,"completionDate":"2025-03-13"},{"nctId":"NCT04198129","phase":"PHASE1","title":"The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-10-01","conditions":["Jaw Fractures","Infection"],"enrollment":13,"completionDate":"2022-03-20"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT06841003","phase":"PHASE3","title":"Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis","status":"NOT_YET_RECRUITING","sponsor":"Spaarne Gasthuis","startDate":"2025-02","conditions":["Complicated Appendicitis","Intra-Abdominal Abscess"],"enrollment":752,"completionDate":"2027-05"},{"nctId":"NCT06787885","phase":"NA","title":"Evaluation of Efficacy and Safety Parameters of Different Antibiotics Regimens for Management of Empyema","status":"RECRUITING","sponsor":"Fayoum University","startDate":"2024-05-01","conditions":["Empyema, Pleural"],"enrollment":90,"completionDate":"2025-05-01"},{"nctId":"NCT04194216","phase":"PHASE3","title":"Antibiotic Prophylaxis in Rhinoplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Stanford University","startDate":"2020-05-20","conditions":["Nasal Obstruction","Nasal Surgical Procedures"],"enrollment":864,"completionDate":"2027-04-20"},{"nctId":"NCT05849090","phase":"EARLY_PHASE1","title":"Vancomycin and Tobramycin Powder Use in Acute Open Fractures","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-27","conditions":["Infections"],"enrollment":10,"completionDate":"2024-12-12"},{"nctId":"NCT05899140","phase":"PHASE4","title":"Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Frieder Schaumburg","startDate":"2024-03-15","conditions":["Skin Infection","Staphylococcal Infections","Staphylococcus Aureus Infection"],"enrollment":100,"completionDate":"2026-07-31"},{"nctId":"NCT06207786","phase":"NA","title":"Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2024-09-01","conditions":["Skin Cancer","Skin Cancer Face","Malignant Cutaneous Adnexal Neoplasm"],"enrollment":0,"completionDate":"2030-05"},{"nctId":"NCT06702345","phase":"NA","title":"Clostridioides Difficile Controlled Human Infection Model","status":"NOT_YET_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-03-01","conditions":["C. Difficile","C. Difficile Infection","Controlled Human Infection"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT06616168","phase":"PHASE1","title":"Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","startDate":"2023-09-01","conditions":["Bacterial Vaginosis"],"enrollment":200,"completionDate":"2027-08-31"},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":["Methicillin-Resistant Staphylococcus Aureus","Bacterial Infections","Staphylococcal Skin Infections"],"enrollment":199,"completionDate":"2024-01-01"},{"nctId":"NCT00836056","phase":"PHASE1","title":"Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-11","conditions":["Healthy"],"enrollment":24,"completionDate":"2003-11"},{"nctId":"NCT00836004","phase":"PHASE1","title":"Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-11","conditions":["Healthy"],"enrollment":24,"completionDate":"2003-11"},{"nctId":"NCT03261830","phase":"PHASE4","title":"Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)","status":"COMPLETED","sponsor":"Sumit Gupta","startDate":"2017-08-18","conditions":["Supracondylar Humerus Fracture","Post Operative Wound Infection"],"enrollment":160,"completionDate":"2023-03-10"},{"nctId":"NCT06541236","phase":"NA","title":"Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix","status":"RECRUITING","sponsor":"Moscow State University of Medicine and Dentistry","startDate":"2019-09-01","conditions":["To Evaluate the Quality of the Newly Formed Cortical Tissue in the Area of the Condylar Condyle Using Different Bone Grafting Materials"],"enrollment":80,"completionDate":"2024-09"},{"nctId":"NCT05867654","phase":"PHASE4","title":"Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Louisville","startDate":"2024-07-31","conditions":["Osteomyelitis of Jaw"],"enrollment":100,"completionDate":"2025-12"},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":290,"completionDate":"2025-06"},{"nctId":"NCT06422221","phase":"PHASE4","title":"An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures","status":"NOT_YET_RECRUITING","sponsor":"University of Santiago de Compostela","startDate":"2024-07-15","conditions":["Bacteremia","Endocarditis"],"enrollment":150,"completionDate":"2025-06-30"},{"nctId":"NCT06068673","phase":"NA","title":"The Potential Impact of Clindamycin on Neurosurgery Patients.","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-03-01","conditions":["Neurologic Complication","Neurosurgery"],"enrollment":44,"completionDate":"2023-12-30"},{"nctId":"NCT06172010","phase":"PHASE4","title":"Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-04-01","conditions":["Prosthetic-joint Infection","Infection Hip","Infection; Knee, Joint"],"enrollment":316,"completionDate":"2028-03"},{"nctId":"NCT06126263","phase":"","title":"Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections","status":"UNKNOWN","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2023-01-01","conditions":["Streptococcal Sepsis","Invasive Group A Beta-Haemolytic Streptococcal Disease","Necrotizing Soft Tissue Infection","Infection, Bloodstream","Infection, Bacterial","Streptococcal Toxic Shock Syndrome"],"enrollment":1000,"completionDate":"2024-06-30"},{"nctId":"NCT03333408","phase":"PHASE4","title":"Determining the Necessity for Postoperative Antibiotics After Salivary Stent Placement","status":"UNKNOWN","sponsor":"Our Lady of the Lake Hospital","startDate":"2018-06-15","conditions":["Salivary Duct"],"enrollment":40,"completionDate":"2024-12-31"},{"nctId":"NCT02579161","phase":"PHASE3","title":"Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2014-09","conditions":["Kidney Stones"],"enrollment":98,"completionDate":"2018-12"},{"nctId":"NCT03945357","phase":"PHASE3","title":"Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2019-05-15","conditions":["Ventral Hernia Repair"],"enrollment":250,"completionDate":"2023-01-09"},{"nctId":"NCT06006663","phase":"PHASE2,PHASE3","title":"Effect of Hebal and Synthetic Medicamentss on Enterococcus Feacalis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-08-26","conditions":["Effective Intracanal Medicaments Against Enterococcus Faecalis"],"enrollment":32,"completionDate":"2023-12-10"},{"nctId":"NCT04751500","phase":"NA","title":"The HYsteroscopic Miscarriage MaNagement Trial: A Pilot RCT Investigating a Novel Management Pathway for RPOC","status":"COMPLETED","sponsor":"Birmingham Women's and Children's NHS Foundation Trust","startDate":"2021-01-31","conditions":["Retained Products After Miscarriage"],"enrollment":149,"completionDate":"2022-11-02"},{"nctId":"NCT05166746","phase":"PHASE2","title":"The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota","status":"UNKNOWN","sponsor":"Peter Humaidan","startDate":"2017-12-07","conditions":["Bacterial Vaginoses","Infertility, Female"],"enrollment":333,"completionDate":"2023-10-01"},{"nctId":"NCT05926869","phase":"PHASE2","title":"Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":["Acne Vulgaris"],"enrollment":100,"completionDate":"2023-02-01"},{"nctId":"NCT05762484","phase":"NA","title":"Efficacy of Laser Hair Removal Therapy in HS","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-04","conditions":["Hidradenitis Suppurativa, Acne Inversa"],"enrollment":58,"completionDate":"2026-04"},{"nctId":"NCT02730962","phase":"PHASE2","title":"Interventional Bioremediation of Microbiota in Metabolic Syndrome","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2016-06","conditions":["Pre-Diabetes"],"enrollment":12,"completionDate":"2018-01"},{"nctId":"NCT05223400","phase":"","title":"Drug Use Evaluation of Clindamycin in Critical Care Units in Alexandria Main University Hospital","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-03-01","conditions":["Infection, Bacterial"],"enrollment":99,"completionDate":"2022-04-01"},{"nctId":"NCT01874860","phase":"PHASE2","title":"Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-08","conditions":["Colorectal Cancer","Head and Neck Cancer"],"enrollment":24,"completionDate":"2018-07"},{"nctId":"NCT04834310","phase":"PHASE4","title":"Postoperative Antibiotics Following Primary and Secondary Breast Augmentation","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":["Surgical Site Infection","Capsular Contracture Associated With Breast Implant","Antibiotic Resistant Infection","Antibiotic Side Effect"],"enrollment":0,"completionDate":"2024-07-30"},{"nctId":"NCT04516148","phase":"PHASE4","title":"A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2018-05-29","conditions":["Burn","Surgery","Infection Wound"],"enrollment":32,"completionDate":"2020-10-30"},{"nctId":"NCT00671749","phase":"PHASE4","title":"Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-12","conditions":["Acne Vulgaris"],"enrollment":100,"completionDate":"2008-08"},{"nctId":"NCT01876628","phase":"PHASE4","title":"Adjunctive Clindamycin for Cellulitis: C4C Trial.","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2013-10","conditions":["Cellulitis"],"enrollment":410,"completionDate":"2016-03"},{"nctId":"NCT01063270","phase":"NA","title":"Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2010-02","conditions":["Hidradenitis Suppurativa"],"enrollment":18,"completionDate":"2013-12"},{"nctId":"NCT03173053","phase":"NA","title":"S. Aureus Decolonization in HPN Patients.","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2018-02-08","conditions":["Staphylococcus Aureus","Motility Disorder"],"enrollment":63,"completionDate":"2021-10-14"},{"nctId":"NCT02809131","phase":"PHASE3","title":"Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-04-01","conditions":["Sick Sinus Syndrome","Complete Heart Block","Syncope","Chronic Systolic Heart Failure"],"enrollment":1010,"completionDate":"2021-09-30"},{"nctId":"NCT03357419","phase":"NA","title":"The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2021-03","conditions":["Skin Lesion"],"enrollment":0,"completionDate":"2022-03-27"},{"nctId":"NCT05268835","phase":"PHASE4","title":"Different Oral Doses of Clindamycin in Preventing Post-operative Sequelae of Lower Third Molar Surgery","status":"UNKNOWN","sponsor":"Oral and Maxillofacial Surgery Clinic, Poland","startDate":"2020-02-01","conditions":["Impacted Third Molar Tooth","Impacted Molar"],"enrollment":300,"completionDate":"2022-10"},{"nctId":"NCT03779295","phase":"NA","title":"Laser Therapy for Perioral Dermatitis","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2018-11-01","conditions":["Perioral Dermatitis"],"enrollment":0,"completionDate":"2019-06-05"},{"nctId":"NCT02515305","phase":"PHASE3","title":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-07","conditions":["Acne"],"enrollment":890,"completionDate":"2016-06"},{"nctId":"NCT05106803","phase":"","title":"Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan","status":"COMPLETED","sponsor":"Yarmouk University","startDate":"2019-08-01","conditions":["Bacterial Infections","Antibiotic Resistant Infection","Surgical Site Infection"],"enrollment":24,"completionDate":"2019-10-01"},{"nctId":"NCT00000640","phase":"PHASE3","title":"A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Pneumonia, Pneumocystis Carinii","HIV Infections"],"enrollment":290,"completionDate":"1994-09"},{"nctId":"NCT01138514","phase":"PHASE3","title":"Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2009-10","conditions":["Acne Vulgaris"],"enrollment":1555,"completionDate":"2010-10"},{"nctId":"NCT03478163","phase":"PHASE4","title":"Antibiotics During Intrauterine Balloon Tamponade Placement","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-03-08","conditions":["Obstetric Complication","Postpartum Hemorrhage","Postpartum Endometritis"],"enrollment":11,"completionDate":"2021-05-03"},{"nctId":"NCT03378427","phase":"NA","title":"Tedizolid Prolonged Treatment for Prosthetic Joint Infections","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2018-08-28","conditions":["Prosthetic Joint Infection"],"enrollment":35,"completionDate":"2021-08-22"},{"nctId":"NCT03779360","phase":"NA","title":"Intradermal LPS and Antibiotics","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-10-12","conditions":["Inflammation; Skin"],"enrollment":32,"completionDate":"2019-02-23"},{"nctId":"NCT04980170","phase":"EARLY_PHASE1","title":"Clindamycin Versus Amoxicillin With Clavulanic Acid in Prevention of Early Dental Implants Failure","status":"UNKNOWN","sponsor":"Jordan University Hospital","startDate":"2021-11-01","conditions":["Antibiotics Causing Adverse Effects in Therapeutic Use"],"enrollment":100,"completionDate":"2022-06-01"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT04723940","phase":"PHASE3","title":"Or v IV Antibiotics for Infection","status":"UNKNOWN","sponsor":"Rothman Institute Orthopaedics","startDate":"2021-01-25","conditions":["Joint Infection"],"enrollment":308,"completionDate":"2023-01-25"},{"nctId":"NCT02585141","phase":"NA","title":"Aspiration Treatment of Perianal Abscess","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2015-10","conditions":["Anal Fistulas"],"enrollment":111,"completionDate":"2020-06"},{"nctId":"NCT04349410","phase":"PHASE2,PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":["CoVid 19 Positive"],"enrollment":1800,"completionDate":"2020-09-14"},{"nctId":"NCT03522441","phase":"PHASE3","title":"Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Akorn, Inc.","startDate":"2018-04-27","conditions":["Acne Vulgaris"],"enrollment":1125,"completionDate":"2019-04-22"},{"nctId":"NCT02475876","phase":"PHASE1","title":"PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children","status":"COMPLETED","sponsor":"Michael Cohen-Wolkowiez","startDate":"2015-11","conditions":["Bacterial Infections"],"enrollment":51,"completionDate":"2020-06-30"},{"nctId":"NCT03374176","phase":"PHASE3","title":"Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in Patients With Periodontitis and Diabetes","status":"COMPLETED","sponsor":"Centro Universitario de Tonalá","startDate":"2014-03","conditions":["Periodontitis","Periodontal Pocket","Diabetes Mellitus"],"enrollment":42,"completionDate":"2017-09"},{"nctId":"NCT03560232","phase":"PHASE4","title":"Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens","status":"TERMINATED","sponsor":"Mercy Health Ohio","startDate":"2018-07-09","conditions":["Open Fracture","Post-Op Wound Infection"],"enrollment":17,"completionDate":"2020-02-19"},{"nctId":"NCT01792804","phase":"PHASE3","title":"Staphylococcus Aureus Bacteremia Antibiotic Treatment Options","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2013-12","conditions":["Staphylococcus Aureus Infection"],"enrollment":215,"completionDate":"2020-03-26"},{"nctId":"NCT02616614","phase":"PHASE3","title":"Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-05","conditions":["Acne Vulgaris"],"enrollment":862,"completionDate":"2015-11"},{"nctId":"NCT03615768","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-08-14","conditions":["Acne Vulgaris"],"enrollment":1617,"completionDate":"2020-04-07"},{"nctId":"NCT02782078","phase":"NA","title":"Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-03-06","conditions":["Staphylococcal Infections"],"enrollment":20,"completionDate":"2019-01-03"},{"nctId":"NCT02860845","phase":"PHASE4","title":"Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections","status":"COMPLETED","sponsor":"Laboratorios Ordesa","startDate":"2016-07-12","conditions":["Candidiasis","Vaginosis, Bacterial"],"enrollment":48,"completionDate":"2017-11-30"},{"nctId":"NCT03257202","phase":"PHASE2","title":"Topical Treatment and Prevalence of P. Acnes","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2017-09-11","conditions":["Surgical Site Infection"],"enrollment":12,"completionDate":"2018-01-01"},{"nctId":"NCT01619410","phase":"NA","title":"Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2012-01","conditions":["Skin Diseases, Bacterial","Abscess"],"enrollment":25,"completionDate":"2016-12"},{"nctId":"NCT04134273","phase":"PHASE1","title":"Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2019-03-20","conditions":["Acne Vulgaris"],"enrollment":1260,"completionDate":"2019-10-15"},{"nctId":"NCT02593383","phase":"PHASE1,PHASE2","title":"Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2015-03-01","conditions":["Acne"],"enrollment":245,"completionDate":"2017-07-31"},{"nctId":"NCT02018094","phase":"PHASE4","title":"The Amputation Surgical Site Infection Trial (ASSIT)","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2013-10-08","conditions":["Wound Infection","Amputation Wound"],"enrollment":160,"completionDate":"2017-01-02"},{"nctId":"NCT01994993","phase":"PHASE2,PHASE3","title":"Antibiotic Safety (SCAMP)","status":"COMPLETED","sponsor":"Michael Cohen-Wolkowiez","startDate":"2013-12","conditions":["Complicated Intra Abdominal Infections"],"enrollment":260,"completionDate":"2017-04-20"},{"nctId":"NCT03883269","phase":"PHASE4","title":"Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients","status":"RECRUITING","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-03-20","conditions":["Acne Vulgaris"],"enrollment":30,"completionDate":"2019-12"},{"nctId":"NCT03742908","phase":"NA","title":"Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-06-16","conditions":["Breast Neoplasms"],"enrollment":291,"completionDate":"2021-10-31"},{"nctId":"NCT02731105","phase":"PHASE4","title":"Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2015-02","conditions":["Acne Vulgaris"],"enrollment":22,"completionDate":"2018-01"},{"nctId":"NCT01047189","phase":"PHASE4","title":"Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2009-03","conditions":["Acne Vulgaris"],"enrollment":26,"completionDate":"2009-10"},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":["Osteomyelitis"],"enrollment":30,"completionDate":"2017-02-02"},{"nctId":"NCT02578043","phase":"PHASE1","title":"A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-04","conditions":["Acne Vulgaris"],"enrollment":844,"completionDate":"2015-09"},{"nctId":"NCT02674191","phase":"NA","title":"Posterior Segment Intrusion Using Miniplates","status":"UNKNOWN","sponsor":"Manal El Namrawy","startDate":"2016-05","conditions":["Orthodontic Anchorage Procedures"],"enrollment":24,"completionDate":"2018-07"},{"nctId":"NCT03412071","phase":"NA","title":"Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2017-12-07","conditions":["Foreskin HIV Susceptibility"],"enrollment":125,"completionDate":"2019-12-07"},{"nctId":"NCT01715610","phase":"NA","title":"Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage","status":"WITHDRAWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-05-24","conditions":["Peritonsillar Abscess"],"enrollment":0,"completionDate":"2015-12-02"},{"nctId":"NCT02141217","phase":"PHASE4","title":"AUGMENTIN™ in Dental Infections","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-21","conditions":["Focal Infection, Dental"],"enrollment":472,"completionDate":"2013-12-28"},{"nctId":"NCT02058628","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-21","conditions":["Acne Vulgaris"],"enrollment":222,"completionDate":"2014-09-08"},{"nctId":"NCT01929278","phase":"PHASE1","title":"W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-12-08","conditions":["Acne Vulgaris"],"enrollment":37,"completionDate":"2008-12-19"},{"nctId":"NCT02465632","phase":"PHASE3","title":"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2015-04","conditions":["Acne Vulgaris"],"enrollment":1100,"completionDate":"2015-12"},{"nctId":"NCT00636935","phase":"PHASE4","title":"Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2008-02","conditions":["Pneumocystis Carinii Pneumonia"],"enrollment":0,"completionDate":"2013-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"LINCOMYCIN"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Lincomycin"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Lincomycin hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"lincomycin hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Lincocin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Lincomycin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"lincomycin"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147891","MMSL":"1950","NDDF":"002793","UNII":"BOD072YW0F","VUID":"4019802","CHEBI":"CHEBI:6472","VANDF":"4018090","INN_ID":"1419","RXNORM":"6398","UMLSCUI":"C0023726","chemblId":"CHEMBL3989551","ChEMBL_ID":"CHEMBL1447","KEGG_DRUG":"D00223","DRUGBANK_ID":"DB01627","PDB_CHEM_ID":" 3QB","PUBCHEM_CID":"3000540","SNOMEDCT_US":"18449009","IUPHAR_LIGAND_ID":"10941","SECONDARY_CAS_RN":"7179-49-9","MESH_DESCRIPTOR_UI":"D008034"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","company":"Pharmacia & Upjohn Company LLC","brandName":"Lincocin","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1964-","companyName":"Pharmacia And Upjohn","relationship":"Original Developer"},{"period":"present","companyName":"Pfizer","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.6 hours","clearance":"2.1 mL/min/kg","bioavailability":"25%","volumeOfDistribution":"1.0 L/kg"},"publicationCount":3164,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01FF02","allCodes":["J01FF02"]},"biosimilarFilings":[],"originalDeveloper":"Pharmacia And Upjohn","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Arthur Grp","Gland","Micro Labs","Slate Run Pharma","Slayback","Xgen Pharms"],"status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1964","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1964-12-29T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:13:53.029244+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}